证券代码：688029 证券简称：南微医学 公告编号：2025-044 南微医学科技股份有限公司 关于股份回购实施结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/4/22，由董事长隆晓辉先生提议 | | | | | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 日~2025 年 10 月 21 日 | 4 | 月 | 22 | | 预计回购金额 | 3,000万元~5,000万元 | | | | | 回购价格上限 | 95.04元/股 | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | □用于转换公司可转债 | | | | | | □为维护公司价值及股东权益 | | | | | 实际回购股数 | 335,084股 | | | | | 实际回购股数占总股本比例 | 0.18% | | | | | 实际回购金额 | 30,021,538.75元 | | | ...

南微医学公告，2025年4月22日至2025年10月21日期间，公司通过集中竞价交易方式回购股份，实际回 购股数为33.51万股，占总股本的0.18%，回购价格区间为62.01元/股至93.76元/股，使用资金总额为 3002.15万元。此次回购的股份将用于员工持股计划或股权激励。 ...

Market Overview - The medical device sector experienced a decline of 1.35% on October 13, with Nanwei Medical leading the drop [1] - The Shanghai Composite Index closed at 3889.5, down 0.19%, while the Shenzhen Component Index closed at 13231.47, down 0.93% [1] Top Performers - Zhendemedical (603301) saw a closing price of 60.44, with a rise of 7.05% and a trading volume of 166,300 shares [1] - Wuzhou Medical (301234) closed at 46.22, up 6.13%, with a trading volume of 32,400 shares [1] - BGI Genomics (688114) closed at 72.35, increasing by 4.99% with a trading volume of 89,300 shares [1] Underperformers - Nanwei Medical (688029) closed at 91.15, down 6.78% with a trading volume of 42,800 shares [2] - Kangzhong Medical (688607) closed at 26.57, down 4.60%, with a trading volume of 25,700 shares [2] - Mindray Medical (300760) closed at 235.20, down 2.81%, with a trading volume of 108,600 shares [2] Capital Flow - The medical device sector saw a net outflow of 412 million yuan from institutional investors, while retail investors contributed a net inflow of 325 million yuan [2][3] - The top net inflow from retail investors was observed in Mindray Medical, with 2.63 million yuan, while Zhendemedical experienced a net outflow of 55.19 million yuan from retail investors [3]

Core Insights - The article discusses the growth and advantages of single-use endoscopes, specifically focusing on single-use biliary endoscopes, which enhance the diagnosis and treatment of biliary diseases through minimally invasive procedures [1][4][5]. Group 1: Industry Overview - Biliary endoscopes allow direct observation of biliary duct lesions and facilitate procedures such as biopsy, stone removal, and dilation of strictures, significantly improving diagnostic and therapeutic efficiency [1][4]. - The global market for single-use biliary endoscopes is projected to grow from $164 million in 2018 to $416 million by 2024, achieving a compound annual growth rate (CAGR) of 16.8% [5][6]. - In China, the market for single-use biliary endoscopes is expected to expand from ¥12 million in 2018 to ¥88 million by 2024, with a remarkable CAGR of 39.9%, outpacing the global market growth [6][8]. Group 2: Market Dynamics - The single-use biliary endoscope market in China is still in its early development stage, characterized by high market concentration, with the top three companies holding 79.4% of the market share and the top five companies accounting for 93.7% [8][9]. - Domestic companies are gaining ground in the single-use biliary endoscope market, with Boston Scientific holding nearly half of the market share, while local firms like Nanwei Medical and Maiketian are rapidly increasing their market presence [8][9]. Group 3: Competitive Landscape - The competitive landscape is currently dominated by a few international medical device companies, but the single-use biliary endoscope sector is seeing a more balanced competition between domestic and international players [8][10]. - The article highlights the emergence of innovative domestic companies focusing on single-use endoscopes, with several products receiving regulatory approval [10][11]. Group 4: Future Trends - The future of the single-use biliary endoscope market is expected to be driven by increased demand for infection control, technological advancements, and supportive policies, leading to rapid global expansion [11][12]. - The integration of AI technology is anticipated to enhance the intelligence of single-use biliary endoscopes, contributing to high-quality medical development [12].

Core Points - Nanwei Medical announced that as of September 30, 2025, the company has repurchased a total of 109,797 shares, which represents 0.0585% of the total share capital [2] Summary by Category - **Share Repurchase** - The company has not repurchased any shares since September 2025 [2] - The total number of shares repurchased to date is 109,797 [2] - The repurchased shares account for 0.0585% of the company's total share capital [2]

Core Viewpoint - Nanwei Medical (688029.SH) has announced a share buyback program, indicating a strategic move to enhance shareholder value and confidence in the company's future prospects [1] Summary by Categories Share Buyback Details - As of September 30, 2025, the company has repurchased a total of 109,797 shares, which represents 0.0585% of the total share capital [1] - The highest purchase price for the shares was 93.76 yuan per share, while the lowest was 62.01 yuan per share [1] - The total amount spent on the buyback, excluding transaction fees such as stamp duty and commissions, is 9,604,989.12 yuan [1]

Group 1 - Company Nanwei Medical (SH 688029) announced on October 9 that as of September 30, 2025, it has repurchased approximately 110,000 shares, accounting for 0.0585% of the total share capital, with a total expenditure of about 9.6 million yuan [1] - The highest purchase price for the repurchased shares was 93.76 yuan per share, while the lowest was 62.01 yuan per share [1] - For the year 2024, the revenue composition of Nanwei Medical is 99.49% from medical devices and 0.51% from other businesses [1] Group 2 - As of the time of reporting, the market capitalization of Nanwei Medical is 18.4 billion yuan [2]

证券代码：688029 证券简称：南微医学 公告编号：2025-043 南微医学科技股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/4/22，由董事长隆晓辉先生提议 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 月 2025 | 4 | 22 | 日~2025 | 年 | 10 | 21 | 日 | | 预计回购金额 | 3,000万元~5,000万元 | | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | | 累计已回购股数 | 109,797股 | | | | | | | | | 累计已回购股数占总股本比例 | 0.0585% | | | | ...

两融数据显示，该股最新融资余额为2.15亿元，近5日减少1016.97万元，降幅为4.52%。 据天眼查APP显示，南微医学科技股份有限公司成立于2000年05月10日，注册资本18784.7422万人民 币。（数据宝） 南微医学9月30日大宗交易平台共发生2笔成交，合计成交量15.00万股，成交金额1505.26万元。成交价 格均为100.35元。 证券时报·数据宝统计显示，南微医学今日收盘价为100.35元，上涨7.52%，日换手率为2.24%，成交额 为4.14亿元，全天主力资金净流入2030.61万元，近5日该股累计上涨11.70%，近5日资金合计净流入 248.35万元。 | 成交量 （万股） | 成交金额 （万元） | 成交价格 （元） | 相对当日收盘折 溢价（%） | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | 7.50 | 752.63 | 100.35 | 0.00 | 招商证券股份有限公司北京 | 广发证券股份有 | | | | | | 景辉街证券营业部 | 限公司总部 | | 7.50 | 752.63 | 100.3 ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 第2笔成交价格为100.35元，成交7.50万股，成交金额752.63万元，溢价率为0.00%，买方营业部为招商 证券股份有限公司北京景辉街证券营业部，卖方营业部为广发证券股份有限公司总部。 进一步统计，近3个月内该股累计发生2笔大宗交易，合计成交金额为1505.26万元。该股近5个交易日累 计上涨11.74%，主力资金合计净流入1896.76万元。 责任编辑：小浪快报 第1笔成交价格为100.35元，成交7.50万股，成交金额752.63万元，溢价率为0.00%，买方营业部为招商 证券股份有限公司北京景辉街证券营业部，卖方营业部为广发证券股份有限公司总部。 9月30日，南微医学收涨7.52%，收盘价为100.35元，发生2笔大宗交易，合计成交量15万股，成交金额 1505.26万元。 ...